FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

HANSEN BRIAN B
2. Issuer Name and Ticker or Trading Symbol

TANDEM DIABETES CARE INC [ TNDM ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
EVP & CHIEF COMMERCIAL OFFICER
(Last)          (First)          (Middle)

11075 ROSELLE ST
3. Date of Earliest Transaction (MM/DD/YYYY)

11/4/2019
(Street)

SAN DIEGO, CA 92121
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  11/4/2019    M    15000  A $2.59  17991  D   
Common Stock  11/4/2019    S(1)    15000  D $62.0087 (2) 2991  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option  $2.59  11/4/2019    M     15000       (3)  (4) Common Stock  15000.0  $0  10000  D   

Explanation of Responses:
(1)  The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 9, 2018 and amended on May 16,2019.
(2)  The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $61.75 and$62.26.
(3)  The option shall vest as to fifty percent (50%) of the underlying shares on 12/01/2018, and the remaining shares shall vest in twelve (12) equalmonthly installments thereafter.
(4)  The expiration date for these options is 10 years from the date of grant.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
HANSEN BRIAN B
11075 ROSELLE ST
SAN DIEGO, CA 92121


EVP & CHIEF COMMERCIAL OFFICER

Signatures
/s/David Berger, Attorney-in-fact for Brian B. Hansen 11/6/2019
**Signature of Reporting Person Date


Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Tandem Diabetes Care Charts.
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Tandem Diabetes Care Charts.

Tandem Diabetes Care Inc News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Tandem Diabetes Care Announces First Quarter 2024 Financial Results and Updates Full Year 2024 Financial Guidance
Thursday 2 May 2024 (2 days ago) • Business Wire
Tandem Diabetes Care Announces Upcoming Conference Presentations
Monday 29 April 2024 (5 days ago) • Business Wire
Tandem Diabetes Care to Announce First Quarter 2024 Financial Results on May 2, 2024
Tuesday 9 April 2024 (4 weeks ago) • Business Wire
Parexel Announces CEO Succession Plan
Monday 18 March 2024 (2 months ago) • GlobeNewswire Inc.
Tandem Diabetes Care Prices Upsized Private Placement of $275.0 Million of Convertible Senior Notes Due 2029
Tuesday 5 March 2024 (2 months ago) • Business Wire
Tandem Diabetes Care Announces Proposed Private Placement of Convertible Notes
Monday 4 March 2024 (2 months ago) • Business Wire
Form 4 - Statement of changes in beneficial ownership of securities
Thursday 29 February 2024 (2 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Thursday 29 February 2024 (2 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Thursday 29 February 2024 (2 months ago) • Edgar (US Regulatory)
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Wednesday 21 February 2024 (2 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Wednesday 21 February 2024 (2 months ago) • Edgar (US Regulatory)
Tandem Diabetes Care Announces Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance
Wednesday 21 February 2024 (2 months ago) • Business Wire